Does metformin have a disease modifying effect in symptomatic knee osteoarthritis? A multicentre randomised, double-blind, placebo-controlled trial

二甲双胍对有症状的膝骨关节炎有改善疾病的作用吗？

• 批准号: nhmrc : GNT1133903
• 负责人: Dr Yuan Lim
• 金额: $ 12.47万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/does-metformin-disease-controlled-trial/1347923
• 关键词: Does; metformin; disease; modifying; effect

Osteoarthritis(OA) is a major contributor to this disease burden. Currently, there is no therapy that slows disease progression. Metformin may affect OA progression via multiple pathways that address the pathogenesis of knee OA, including weight loss, glucose- and lipid-lowering, and anti-inflammation. This will be the world first randomised, double-blind controlled trial, to assess the effect of metformin, compared with placebo, on knee OA-related structural and clinical outcomes

骨关节炎（OA）是这种疾病负担的主要因素。目前，没有减慢疾病进展的疗法。二甲双胍可能会通过多种途径影响OA的进展，这些途径解决了膝关节的发病机理，包括体重减轻，葡萄糖和降低脂质以及抗炎。这将是世界上首次随机，双盲对照试验，以评估二甲双胍的作用，与安慰剂相比，对膝关节OA相关的结构和临床结果